FORE Biotherapeutics has raised a total of $113 million in the Series D financing, with significant investor backing and promising early clinical data for plixorafenib.
Company Description
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Market
Oncology
Location
Philadelphia,
Pennsylvania,
United States
Coinvestors
SR One, Medicxi, OrbiMed, HBM Healthcare Investments, Wellington Management, Novartis Venture Fund, Cormorant Asset Management, 3B Future Health Fund